IPP Bureau
Bliss GVS Pharma Q1 FY2024 consolidated PAT up at Rs. 14.68 Cr
By IPP Bureau - August 02, 2023
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
Lupin receives approval from US FDA for Turqoz
By IPP Bureau - August 02, 2023
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
Syrma SGS acquires majority sake in Johari Digital Healthcare
By IPP Bureau - August 02, 2023
JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices
Fredun Pharmaceuticals achieves milestone in Pet Care Division
By IPP Bureau - August 01, 2023
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
Shilpa Medicare lunches pemetrexed injection in India under the brand name VRTU
By IPP Bureau - August 01, 2023
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries
By IPP Bureau - August 01, 2023
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Concord Biotech’s IPO to open on 4th August, 2023
By IPP Bureau - August 01, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer
By IPP Bureau - August 01, 2023
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Fluor awarded more than $1 billion in life sciences contracts
By IPP Bureau - August 01, 2023
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
Biogen to acquire Reata Pharmaceuticals
By IPP Bureau - July 31, 2023
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
USFDA accepts biologics license application for GC Biopharma's GC5107B
By IPP Bureau - July 31, 2023
New products and nutraceuticals added under Jan Aushadhi Pariyojana
By IPP Bureau - July 31, 2023
The product basket increased to 1800 medicines and 285 Surgical Equipment
Mandaviya chairs 7th meeting of Central Institute Body of AIIMS and Chintan Shivir at NIHFW, Delhi
By IPP Bureau - July 31, 2023
Chintan Shivir has provided a platform to hold discussions with higher officials and experts, which will help in evolving better practices of premier health institutions like AIIMS
Govt. exhorts doctors to prescribe generic gedicines
By IPP Bureau - July 31, 2023
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive
By IPP Bureau - July 29, 2023
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
